FULCRUM THERAPEUTICS, INC. Earnings Per Share (Diluted)
FULCRUM THERAPEUTICS, INC. (FULC) reported Earnings Per Share (Diluted) of -$0.34 per share for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.34.
- FULCRUM THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.25.
- FULCRUM THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.31.
- FULCRUM THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.31.
- FULCRUM THERAPEUTICS, INC. earnings per share, diluted for fiscal 2023 was -$1.59.
- FULCRUM THERAPEUTICS, INC. earnings per share, diluted for fiscal 2022 was -$2.44.
- FULCRUM THERAPEUTICS, INC. earnings per share, diluted for fiscal 2021 was -$2.29.
- FULCRUM THERAPEUTICS, INC. earnings per share, diluted for fiscal 2020 was -$2.79.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.34 S-4 · filed 2026-09-02 | -$0.59 S-4 · filed 2026-09-02 | -$0.90 derived: net income ÷ weighted average shares · filed 2026-09-02 | -$1.21 derived: net income ÷ weighted average shares · filed 2026-09-02 |
| 2026-03-31 | -$0.25 10-Q · filed 2026-04-27 | -$0.55 derived: net income ÷ weighted average shares · filed 2026-09-02 | -$0.86 derived: net income ÷ weighted average shares · filed 2026-09-02 | -$1.14 derived: net income ÷ weighted average shares · filed 2026-09-02 |
| 2025-12-31 | -$0.31 derived: net income ÷ weighted average shares · filed 2026-09-02 | -$0.62 derived: net income ÷ weighted average shares · filed 2026-09-02 | -$0.90 derived: net income ÷ weighted average shares · filed 2026-09-02 | -$1.18 S-4 · filed 2026-09-02 |
| 2025-09-30 | -$0.31 10-Q · filed 2025-10-29 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-09-02 | -$0.87 10-Q · filed 2025-10-29 | -$1.16 derived: net income ÷ weighted average shares · filed 2026-09-02 |
| 2025-06-30 | -$0.28 S-4 · filed 2026-09-02 | -$0.56 S-4 · filed 2026-09-02 | -$0.85 derived: net income ÷ weighted average shares · filed 2026-09-02 | -$1.20 derived: net income ÷ weighted average shares · filed 2026-09-02 |
| 2025-03-31 | -$0.28 10-Q · filed 2026-04-27 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-09-02 | -$0.92 derived: net income ÷ weighted average shares · filed 2026-09-02 | -$0.01 derived: net income ÷ weighted average shares · filed 2026-09-02 |
| 2024-12-31 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-09-02 | -$0.64 derived: net income ÷ weighted average shares · filed 2026-09-02 | $0.28 derived: net income ÷ weighted average shares · filed 2026-09-02 | -$0.16 S-4 · filed 2026-09-02 |
| 2024-09-30 | -$0.35 10-Q · filed 2025-10-29 | $0.54 derived: net income ÷ weighted average shares · filed 2025-10-29 | $0.11 10-Q · filed 2025-10-29 | -$14.74 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2024-06-30 | $0.87 10-Q · filed 2025-07-29 | $0.45 10-Q · filed 2025-07-29 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$18.93 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2024-03-31 | -$0.43 10-Q · filed 2025-05-01 | $0.85 derived: net income ÷ weighted average shares · filed 2026-04-30 | $3.83 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$160.16 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2023-12-31 | $0.14 derived: net income ÷ weighted average shares · filed 2026-04-30 | $0.80 derived: net income ÷ weighted average shares · filed 2026-04-30 | $3.66 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.59 10-K · filed 2025-02-25 |
| 2023-09-30 | -$0.39 10-Q · filed 2024-11-13 | -$0.77 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$1.19 10-Q · filed 2024-11-13 | -$3.19 derived: net income ÷ weighted average shares · filed 2024-11-13 |
| 2023-06-30 | -$0.38 10-Q · filed 2024-07-31 | -$0.80 10-Q · filed 2024-07-31 | -$3.62 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$6.36 derived: net income ÷ weighted average shares · filed 2024-11-13 |
| 2023-03-31 | -$0.41 10-Q · filed 2024-05-13 | -$910.18 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$1416.64 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$2185.59 derived: net income ÷ weighted average shares · filed 2024-11-13 |
| 2022-12-31 | -$501.10 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$1014.01 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$1808.36 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$2.44 10-K · filed 2024-02-27 |
| 2022-09-30 | -$0.51 10-Q · filed 2023-11-07 | -$1327.35 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$1.97 10-Q · filed 2023-11-07 | -$2547.07 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2022-06-30 | -$0.83 10-Q · filed 2023-08-03 | -$1.47 10-Q · filed 2023-08-03 | -$2050.00 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$2625.05 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2022-03-31 | -$0.64 10-Q · filed 2023-05-15 | -$1215.86 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$1784.65 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$2385.74 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2021-12-31 | -$577.93 derived: net income ÷ weighted average shares · filed 2023-06-26 | -$1144.47 derived: net income ÷ weighted average shares · filed 2023-06-26 | -$1743.26 derived: net income ÷ weighted average shares · filed 2023-06-26 | -$2.29 10-K/A · filed 2023-06-26 |
| 2021-09-30 | -$0.57 10-Q · filed 2022-11-08 | -$1165.88 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$1.71 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$0.60 10-Q · filed 2022-08-11 | -$1.14 10-Q · filed 2022-08-11 | ||
| 2020-12-31 | -$2.79 10-K/A · filed 2023-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |